TScan Therapeutics appoints Gavin MacBeath as permanent CEO with increased compensation

TScan Therapeutics, Inc.

Gavin MacBeath, Ph.D., appointed CEO and Class I Director effective May 24, 2023; previously acting CEO since March 2023.
Base salary increased to $565,000 (from $470,000); target bonus raised to 50% of base (from 40%).
Received stock option award for 1,121,300 shares at $2.49 per share; contingent on stockholder approval of equity plan amendment.
Board also granted options for 7,403,100 shares aggregate to other recipients, subject to same amendment.
Company highlights progress in hematologic and solid tumor programs, and collaboration with Amgen for Crohn's disease.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gavin MacBeath

Director

TCRX · TScan Therapeutics, Inc.

Effective: 2023-05-24
Filed: May 31, 2023, 7:59 PM ET

appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.

Appointed

Gavin MacBeath

Chief Executive Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2023-05-24
Filed: May 31, 2023, 7:59 PM ET

appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin MacBeath was appointed as Director at TScan Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin MacBeath was appointed as Chief Executive Officer at TScan Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-157286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.